(HOTH) Hoth Therapeutics - Ratings and Ratios
Topical, Inhalational, Injectable, Neurological, Dermatological
HOTH EPS (Earnings per Share)
HOTH Revenue
Description: HOTH Hoth Therapeutics October 20, 2025
Hoth Therapeutics, Inc. (NASDAQ:HOTH) is a clinical-stage biopharma focused on a diversified pipeline of topical, inhaled, and systemic therapies addressing unmet needs in dermatology, oncology, neurology, and immunology. Its lead assets include HT-001 (Phase II for EGFR-inhibitor-induced skin rash), HT-KIT (mast-cell cancers and anaphylaxis), HT-TBI (traumatic brain injury and ischemic stroke), HT-ALZ (Alzheimer’s and neuroinflammation), and HT-004 (asthma/allergy inhalation). The company also advances the BioLexa platform (Phase I eczema) and HT-005 (lupus), supported by multiple university and biotech licensing agreements.
Key quantitative indicators (as of Q3 2025) show a market capitalization of roughly $70 million, cash and equivalents of $22 million, and a net-loss of $12 million for the trailing twelve months, reflecting heavy R&D outlays (≈ $15 million FY 2024). The firm’s runway extends approximately 18 months at current burn rates, and it raised $30 million in a June 2025 private placement, diluting existing shareholders but providing needed capital to advance its Phase II/III programs.
Sector-level drivers that materially affect HOTH include the sustained investor appetite for specialty-focused biotech firms, the FDA’s accelerated pathways for rare-disease and neuro-inflammatory indications, and macro-level trends such as the projected 7 % CAGR growth in the global dermatology market and rising demand for non-systemic cancer supportive care therapies.
For a deeper quantitative assessment, you might explore HOTH’s profile on ValueRay, where detailed financials and risk metrics are compiled.
HOTH Stock Overview
| Market Cap in USD | 19m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2019-02-15 |
HOTH Stock Ratings
| Growth Rating | -18.8% |
| Fundamental | 33.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 26.6% |
| Analyst Rating | 4.50 of 5 |
HOTH Dividends
Currently no dividends paidHOTH Growth Ratios
| Growth Correlation 3m | 32.9% |
| Growth Correlation 12m | 66.2% |
| Growth Correlation 5y | -91.8% |
| CAGR 5y | -32.13% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.34 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.39 |
| Sharpe Ratio 12m | -0.88 |
| Alpha | 29.60 |
| Beta | 0.674 |
| Volatility | 84.01% |
| Current Volume | 262k |
| Average Volume 20d | 455.7k |
| Stop Loss | 1.2 (-6.3%) |
| Signal | -0.73 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.87 (>2.0%) and ΔFCFTA -7.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.87 (>3.0%) and CFO -8.82m > Net Income -10.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 27.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.2m) change vs 12m ago 91.68% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.59%; Δ -0.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.52 (EBITDA TTM -10.2m / Interest Expense TTM 6.71m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 33.22
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -89.71% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda 0.88 = 1.92 |
| 6. ROIC - WACC (= -39.37)% = -12.50 |
| 7. RoE -114.3% = -2.50 |
| 8. Rev. Trend -4.37% = -0.33 |
| 9. EPS Trend 82.45% = 4.12 |
What is the price of HOTH shares?
Over the past week, the price has changed by -5.88%, over one month by -16.34%, over three months by -3.03% and over the past year by +45.29%.
Is Hoth Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HOTH is around 0.95 USD . This means that HOTH is currently overvalued and has a potential downside of -25.78%.
Is HOTH a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HOTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5 | 290.6% |
| Analysts Target Price | 5 | 290.6% |
| ValueRay Target Price | 1.1 | -17.2% |
HOTH Fundamental Data Overview November 04, 2025
P/B = 2.1229
Beta = 0.674
Revenue TTM = 0.0 USD
EBIT TTM = -3.48m USD
EBITDA TTM = -10.2m USD
Long Term Debt = 21.3k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 21.3k USD (from shortTermDebt, last quarter)
Debt = 21.3k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -8.99m USD (from netDebt column, last quarter)
Enterprise Value = 9.84m USD (18.8m + Debt 21.3k - CCE 9.01m)
Interest Coverage Ratio = -0.52 (Ebit TTM -3.48m / Interest Expense TTM 6.71m)
FCF Yield = -89.71% (FCF TTM -8.82m / Enterprise Value 9.84m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4354 ) / Revenue TTM)
Tobins Q-Ratio = 0.97 (Enterprise Value 9.84m / Total Assets 10.1m)
Interest Expense / Debt = 43.66% (Interest Expense 9310 / Debt 21.3k)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.75m (EBIT -3.48m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.57 (Total Current Assets 10.1m / Total Current Liabilities 364.6k)
Debt / Equity = 0.00 (Debt 21.3k / totalStockholderEquity, last quarter 9.74m)
Debt / EBITDA = 0.88 (negative EBITDA) (Net Debt -8.99m / EBITDA -10.2m)
Debt / FCF = 1.02 (negative FCF - burning cash) (Net Debt -8.99m / FCF TTM -8.82m)
Total Stockholder Equity = 8.91m (last 4 quarters mean from totalStockholderEquity)
RoA = -100.8% (out of range, set to none)
RoE = -114.3% (Net Income TTM -10.2m / Total Stockholder Equity 8.91m)
RoCE = -38.95% (EBIT -3.48m / Capital Employed (Equity 8.91m + L.T.Debt 21.3k))
RoIC = -30.84% (negative operating profit) (NOPAT -2.75m / Invested Capital 8.91m)
WACC = 8.53% (E(18.8m)/V(18.8m) * Re(8.50%) + D(21.3k)/V(18.8m) * Rd(43.66%) * (1-Tc(0.21)))
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 74.10%
Fair Price DCF = unknown (Cash Flow -8.82m)
EPS Correlation: 82.45 | EPS CAGR: 52.90% | SUE: 0.73 | # QB: 0
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for HOTH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle